|
1
|
Lloyd-Jones D, Adams RJ, Brown TM, et al:
Heart disease and stroke statistics - 2010 update: a report from
the American Heart Association. Circulation. 121:e46–e215. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Roger VL, Go AS, Lloyd-Jones DM, et al:
Heart disease and stroke statistics - 2012 update: a report from
the American Heart Association. Circulation. 125:e2–e220. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Owan TE and Redfield MM: Epidemiology of
diastolic heart failure. Progr Cardiovasc Dis. 47:320–332. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ellis ER and Josephson ME: Heart failure
and tachycardia-induced cardiomyopathy. Curr Heart Fail Rep.
10:296–306. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yancy CW: Heart failure in African
Americans. Am J Cardiol. 96:3i–12i. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Thomas KL, Piccini JP, Liang L, et al:
Racial differences in the prevalence and outcomes of atrial
fibrillation among patients hospitalized with heart failure. J Am
Heart Assoc. 2:e0002002013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Neubauer S: The failing heart - an engine
out of fuel. N Engl J Med. 356:1140–1151. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Giordano FJ: Oxygen, oxidative stress,
hypoxia, and heart failure. J Clin Invest. 115:500–508. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
White M, Ducharme A, Ibrahim R, et al:
Increased systemic inflammation and oxidative stress in patients
with worsening congestive heart failure: improvement after
short-term inotropic support. Clin Sci (Lond). 110:483–489. 2006.
View Article : Google Scholar
|
|
10
|
Hare JM: Oxidative stress and apoptosis in
heart failure progression. Circ Res. 89:198–200. 2001.PubMed/NCBI
|
|
11
|
Sawyer DB, Siwik DA, Xiao L, et al: Role
of oxidative stress in myocardial hypertrophy and failure. J Mol
Cell Cardiol. 34:379–388. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Abbate A, Bussani R, Amin MS, Vetroec GW,
et al: Acute myocardial infarction and heart failure: role of
apoptosis. Int J Biochem Cell Biol. 38:1834–1840. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang RP, Yao Q, Xiao YB, et al: Toll-like
receptor 4/nuclear factor-kappa B pathway is involved in myocardial
injury in a rat chronic stress model. Stress. 14:567–575. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gordon JW, Shaw JA and Kirshenbaum LA:
Multiple facets of NF-κB in the heart: to be or not to NF-κB. Circ
Res. 108:1122–1132. 2011.
|
|
15
|
Frantz S, Hu K, Bayer B, et al: Absence of
NF-kappaB subunit p50 improves heart failure after myocardial
infarction. FASEB. 20:1918–1920. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Galang N, Sasaki H and Maulik N: Apoptotic
cell death during ischemia/reperfusion and its attenuation by
antioxidant therapy. Toxicology. 148:111–118. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jones SM, Kirby MS, Harding SE, et al:
Adriamycin cardiomyopathy in the rabbit: alterations in contractile
proteins and myocyte function. Cardiovasc Res. 24:834–842. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Andre L, Fauconnier J, Reboul C, et al:
Subendocardial increase in reactive oxygen species production
affects regional contractile function in ischemic heart failure.
Antioxid Redox Signal. 18:1009–1020. 2013. View Article : Google Scholar
|
|
19
|
van Dalen EC, Caron HN, Dickinson HO, et
al: Cardioprotective interventions for cancer patients receiving
anthracyclines. Cochrane Database Syst Rev. 15:CD0039172011.
|
|
20
|
Carvalho FS, Burgeiro A, Garcia R, et al:
Doxorubicin-induced cardiotoxicity: from bioenergetic failure and
cell death to cardiomyopathy. Med Res Rev. 34:106–135. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dolinsky VW, Rogan KJ, Sung MM, et al:
Both aerobic exercise and resveratrol supplementation attenuate
doxorubicin-induced cardiac injury in mice. Am J Physiol Endocrinol
Metab. 305:E243–E253. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Langton D, Jover B, McGrath BP, et al:
Cardiovascular responses to graded treadmill exercise during the
development of doxorubicin induced heart failure in rabbits.
Cardiovasc Res. 24:959–968. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sarandol A, Sarandol E, Eker SS, et al:
Major depressive disorder is accompanied with oxidative stress:
short-term antidepressant treatment does not alter
oxidative-antioxidative systems. Hum Psychopharmacol. 22:67–73.
2007. View
Article : Google Scholar
|
|
24
|
Erel O: A novel automated method to
measure total antioxidant response against potent free radical
reactions. Clin Biochem. 37:112–119. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ye J, Ding M, Zhang X, et al: On the role
of hydroxyl radical and the effect of tetrandrine on nuclear
factor-κB activation by phorbol 12-myristate 13-acetate. Ann Clin
Lab Sci. 30:65–71. 2000.
|
|
26
|
Kone BC, Schwöbel J, Turner P, et al: Role
of NF-kappa B in the regulation of inducible nitric oxide synthase
in an MTAL cell line. Am J Physiol. 269:F718–F729. 1995.PubMed/NCBI
|
|
27
|
Kubin AM, Skoumal R, Tavi P, et al: Role
of reactive oxygen species in the regulation of cardiac
contractility. J Mol Cell Cardiol. 50:884–893. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Finn NA and Kemp ML: Pro-oxidant and
antioxidant effects of N-acetylcysteine regulate
doxorubicin-induced NF-kappa B activity in leukemic cells. Mol
Biosyst. 8:650–662. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sagristá ML, García AE, Africa De
Madariaga M, et al: Antioxidant and pro-oxidant effect of the
thiolic compounds N-acetyl-L-cysteine and glutathione against free
radical-induced lipid peroxidation. Free Radic Res. 36:329–340.
2002.PubMed/NCBI
|
|
30
|
The Criteria Committee of the New York
Heart Association. Nomenclature and Criteria for Diagnosis of
Diseases of the Heart and Great Vessels. 9th edition. Little, Brown
& Co; Boston: pp. 253–256. 1994
|
|
31
|
You JS, Huang HF and Chang YL: Panax
ginseng reduces adriamycin-induced heart failure in rats. Phytother
Res. 19:1018–1022. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dong JW, Zhu HF, Zhu WZ, et al:
Intermittent hypoxia attenuates ischemia/reperfusion induced
apoptosis in cardiac myocytes via regulating Bcl-2/Bax expression.
Cell Res. 13:385–391. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sabbah HN, Sharov VG, Gupata RC, et al:
Chronic therapy with metoprolol attenuates cardiomyocyte apoptosis
in dogs with heart failure. J Am Coll Cardiol. 36:1698–1705. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Burke JR: Targeting I kappa B kinase for
the treatment of inflammatory and other disorders. Curr Opin Drug
Discov Devel. 6:720–728. 2003.PubMed/NCBI
|
|
35
|
Squadrito F, Deodato B, Squadrito G, et
al: Gene transfer of IkappaBalpha limit infarct
ischemia-reperfusion injury. Lab Invest. 83:1097–1104. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Altavilla D, Deodato B, Campo GM, et al:
IRFI 042, a novel dual vitamin E-like antioxidant, inhibits
activation of nuclear factor-kappaB and reduces the inflammatory
response in myocardial ischemia-reperfusion injury. Cardiovasc Res.
47:515–528. 2000. View Article : Google Scholar
|
|
37
|
Monaco C and Paleolog E: Nuclear factor
kappaB: a potential therapeutic target in atherosclerosis and
thrombosis. Cardiovasc Res. 61:671–682. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Maier HJ, Schips TG, Wietelmann A, et al:
Cardiomyocyte-specific IκB kinase (IKK)/NF-κB activation induces
reversible inflammatory cardiomyopathy and heart failure. Proc Natl
Acad Sci USA. 109:11794–11799. 2012.
|
|
39
|
Hall G, Hasday JD and Rogers TB:
Regulating the regulator: NF-kappaB signaling in heart. J Mol Cell
Cardiol. 41:580–591. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pye J, Ardeshirpour F, McCain A, et al:
Proteasome inhibition ablates activation of NF-kappa B in
myocardial reperfusion and reduces reperfusion injury. Am J Physiol
Heart Circ Physiol. 284:H919–H926. 2003.PubMed/NCBI
|
|
41
|
Gao Y, Lecker S, Post MJ, et al:
Inhibition of ubiquitin-proteasome pathway-mediated I kappa B alpha
degradation by a naturally occurring antibacterial peptide. J Clin
Invest. 106:439–448. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Inserte J, Taimor G, Hofstaetter B, et al:
Influence of simulated ischemia on apoptosis induction by oxidative
stress in adult cardiomyocytes of rat. Am J Physiol Heart Circ
Physiol. 278:H94–H99. 2000.PubMed/NCBI
|
|
43
|
Crespo MJ, Cruz N, Altieri PI, et al:
Chronic treatment with N-acetylcysteine improves cardiac function
but does not prevent progression of cardiomyopathy in Syrian
cardiomyopathic hamsters. J Cardiovasc Pharmacol Ther. 16:197–204.
2011. View Article : Google Scholar
|
|
44
|
Haleagrahara N, Julian V and Chakravarthi
S: N-acetylcysteine offers cardioprotection by decreasing cardiac
lipid hydroperoxides and 8-isoprostane level in
isoproterenol-induced cardiotoxicity in rats. Cardiovasc Toxicol.
11:373–381. 2011. View Article : Google Scholar
|
|
45
|
Basha RH and Priscilla DH: An in vivo and
in vitro study on the protective effects of N-acetylcysteine on
mitochondrial dysfunction in isoproterenol treated myocardial
infarcted rats. Exp Toxicol Pathol. 65:7–14. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Adamy C, Le Corvoisier P, Candiani G, et
al: Tumor necrosis factor alpha and glutathione interplay in
chronic heart failure. Arch Mal Coeur Vaiss. 98:906–912.
2005.PubMed/NCBI
|
|
47
|
Chen F, Hadfield JM, Berzingi C, et al:
N-acetylcysteine reverses cardiac myocyte dysfunction in a rodent
model of behavioral stress. J Appl Physiol. 1985. 115:514–524.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wang T, Qiao S, Lei S, et al:
N-acetylcysteine and allopurinol synergistically enhance cardiac
adiponectin content and reduce myocardial reperfusion injury in
diabetic rats. PLoS One. 6:e239672011. View Article : Google Scholar
|
|
49
|
Dresdale AR, Barr LH, Bonow RO, et al:
Prospective randomized study of the role of N-acetyl cysteine in
reversing doxorubicin-induced cardiomyopathy. Am J Clin Oncol.
5:657–663. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Jo SH, Kim LS, Kim SA, et al: Evaluation
of short-term use of N-acetylcysteine as a strategy for prevention
of anthracycline-induced cardiomyopathy: EPOCH trial - a
prospective randomized study. Korean Circ J. 43:174–181. 2013.
View Article : Google Scholar : PubMed/NCBI
|
